Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Corbus Pharmaceuticals but lowers the price target from $85 to $51.
September 20, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Corbus Pharmaceuticals but lowers the price target from $85 to $51.
The Outperform rating suggests a positive outlook, but the lowered price target indicates reduced expectations for future growth. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100